TGINSIGHT SIMILAR POSTS
Source channel @githubtrending · Post #15021 · Aug 1
#go#argocd#cloud_native#cncf#container_management#devops#ebpf#hacktoberfest#istio#jenkins#k8s#kubernetes#kubernetes_platform_solution#kubesphere#llm#multi_cluster#observability#servicemesh KubeSphere is an easy-to-use, open-source platform that helps you manage Kubernetes clusters across clouds, data centers, and edge devices from one place. It offers a friendly web interface, supports multi-cluster and multi-tenant management, and automates DevOps tasks like CI/CD pipelines. You get built-in monitoring, logging, alerting, and security features such as role-based access control. It also includes an App Store for quick deployment of applications and supports various storage and networking options. This makes managing complex Kubernetes environments simpler, faster, and more secure, saving you time and reducing operational challenges. https://github.com/kubesphere/kubesphere
Search: #clinicalstage
@venturevillagewall · Post #3534 · 12/20/2024, 09:31 AM
$2.16M Fundraising by Umecrine Umecrine Cognition, a Swedish clinical-stage pharmaceutical firm, has raised $2.16 million to advance its innovative drug development targeting neurological disorders. The funding round took place on December 19, 2024. #UmecrineCognition#Pharmaceuticals#NeurologicalDisorders#Funding#Healthcare#ClinicalStage#Sweden
@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM
PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment
@venturevillagewall · Post #3412 · 12/18/2024, 12:11 PM
$60M Funding for Psioxus Psioxus Therapeutics has successfully secured $60M in funding as part of its latest round, scheduled for December 17, 2024. This funding aims to advance its innovative tumor gene therapy platform focused on improving cancer treatment outcomes. #Funding#Cancer#Biotech#Oncology#GeneTherapy#Therapeutics#ClinicalStage#Investment#Healthcare#Psioxus#AkamisBio#Tumor#LifeScience#MedicalResearch#Therapy#Innovative#Impact#Technology#Platform